Important Drug Recall Notice

TO ALL PARTICIPATING PHARMACIES

Circular Letter MC26-019-CG
August 25, 2026

FDA announced that, Vitruvias Therapeutics Inc. is voluntarily recalling one lot (Lot. No. 504950) of Thyroid Tablets, USP 30 mg to the consumer level. The product is being recalled because testing confirmed the potential for the product to be superpotent.

RECOMMENDATIONS

1. Vitruvias Therapeutics is proactively notifying its wholesalers by email and phone to discontinue distribution of the product being recalled and is arranging for destruction of all recalled product. Patients who are currently taking Thyroid, USP from Lot 504950, which is being recalled, should not discontinue use without contacting their healthcare provider for further guidance and/or a replacement prescription.

2. Consumers with questions about the recall can contact Vitruvias Therapeutics, Inc. by email at safety@vitruvias.com or by phone at (256) 239-9373 Monday through Friday from 9 a.m. to 5 p.m. CT.

3. Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product.

4. Review your inventory to identify existence of recalled products.

5. Expect patients to visit your pharmacy to deliver recalled products and prepare your pharmacy staff on how to handle the situation.

Cordially,

MC-Rx Pharmacy Services Department

T. (800) 377-1037
1267 Professional Pkwy, Gainesville, GA 30507
T. (787) 286-6032
Call Box 4908, Caguas, P.R. 00726
MC-Rx.com

Vitruvias Therapeutics, Inc Issues Nationwide Recall of One Lot of Thyroid Tablets, USP 30 mg Due to Potential Super Potency

SUMMARY

Company Announcement Date:	August 21, 2026
FDA Publish Date:	August 24, 2026
Product Type:	Drugs
Reason for Announcement:	Potential for the Product to be Superpotent
Company Name:	Vitruvias Therapeutics, Inc
Brand Name:	Vitruvias Therapeutics
Product Description:	Thyroid Tablets, USP 30 mg

Company Announcement

AUBURN, Ala. (August 21, 2026) – Vitruvias Therapeutics Inc. is voluntarily recalling one lot (Lot. No. 504950) of Thyroid Tablets, USP 30 mg to the consumer level. The product is being recalled because testing confirmed the potential for the product to be superpotent.

Risk Statement: Consumption of superpotent Thyroid tablets can cause hyperthyroidism (overactive thyroid) including, but not limited to, weight loss, heat intolerance, fatigue, nervousness, muscle weakness, hypertension, chest pain, rapid heart rate, or heart rhythm disturbances. The patient population at greater risk from superpotent thyroid are elderly, pregnant women, and infants, especially over extended periods of time. Excess levels of thyroid hormones in the elderly have been associated with adverse outcomes, particularly to cardiac health. Overtreatment of hypothyroidism in pregnancy is associated with a higher rate of maternal and fetal complications, including premature delivery and low birth weight. Overtreatment of hypothyroidism in infants may have negative effects on growth and development. To date, Vitruvias Therapeutics has not received any reports of adverse events known to be related to this recall.

Thyroid, USP is a natural preparation derived from porcine thyroid glands composed of levothyroxine and liothyronine and used to treat hypothyroidism (underactive thyroid).

To best identify the product, the NDC, Product Description, Lot Number, and Expiration Date are listed below.

T. (800) 377-1037
1267 Professional Pkwy, Gainesville, GA 30507
T. (787) 286-6032
Call Box 4908, Caguas, P.R. 00726
MC-Rx.com

Product	NDC	Lot	Exp Date	Units Released	Units Sold	First Distribution Date	Last Distribution Date
Thyroid Tablets, USP 30 mg	69680-166-00	504950	9/30/2026	3,655	1955	1/31/2025	9/30/2025

Lot 504950 was distributed nationwide in the USA to Vitruvias Therapeutics' direct accounts from Jan. 31, 2025 to Sept. 30, 2025.

See product label for ease in identifying the product.

Vitruvias Therapeutics is proactively notifying its wholesalers by email and phone to discontinue distribution of the product being recalled and is arranging for destruction of all recalled product. Patients who are currently taking Thyroid, USP from Lot 504950, which is being recalled, should not discontinue use without contacting their healthcare provider for further guidance and/or a replacement prescription.

Consumers with questions about the recall can contact Vitruvias Therapeutics, Inc. by email at safety@vitruvias.com or by phone at (256) 239-9373 Monday through Friday from 9 a.m. to 5 p.m. CT. Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product.

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.

- Complete and submit the report **Online**
- **Regular Mail or Fax:** Download form or call **1-800-332-1088** to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to **1-800-FDA-0178**.

T. (800) 377-1037
1267 Professional Pkwy, Gainesville, GA 30507
T. (787) 286-6032
Call Box 4908, Caguas, P.R. 00726
MC-Rx.com